EFTA00450648.pdf

From: Lesley Groff To: Jefffrey Epstein Subject: Fwd: Intro via Dr Jeff Port - Angiocrine Bioscience Update Date: Sun, 07 May 2017 20:10:15 +0000 Attachments: Angiocrine_Bioscienceinvestor May_2017_v170504_1813.pdf; Angiocrinen Series_A- I_Equity_Term_Sheet_FINAL.pdf Sent from my iPhone Begin forwarded message: From: Paul Finnegan • Date: May 7, 2017 at 4:03:08 PM EDT To: " Cc: Jeffrey Port Subject: RE: Intro via Di- Jeff Port - Angiocrine Bioscience Update Dear Jeffrey, Hope this email finds all is well with you and your family. It's been about a year-and-a-half since we met at your residence in Manhattan. Since then Angiocrine team and programs have progressed forward. We moved the company to San Diego. We were awarded a $3.8M non-dilutive grant from CIRM, the State of California funding agency for regenerative medicine and stem cell therapy. That grant funded 80% of our work in completing FDA mandated tests prior to entering into human testing. We then recently filed our first investigational new drug (IND) application from the FDA. We expect to get a 'green light' to proceed shortly. We are planning to starting our first clinical trial using a combination of cord blood stem cells cultured and expanded with our proprietary human engineered endothelial (E-CEL) cells. First patients to treat, as suggested by the FDA, is in patients who have leukemia with high-risk cytogenetics. This first trial not only serves as a first step to developing a cure in high-risk leukemia but also serves as a safety trial for other indications such as sickle cell anemia and recovery of severe side effects in cancer patients who are treated with high-dose radiation and/or high-dose chemotherapy. We are on track in applying for an additional $4-5M from CIRM in the form of a non-dilutive clinical grant because of our success in the pre-clinical stage (which was funded by the $3.8M from CIRM). This new clinical grant is a 'matching' grant, where we need to raise $4-6M ($2M goes to our first trial with total cost of $7M and the remainder represents on-going research & operations, minimum 1 year with 2 years preferred). Meanwhile, we have progressed our other research programs including our 2nd proprietary technology, Psi-CEL, which can convert endothelial cells to blood stem cells, in animals. We consider this new program not only to have transformative potential in cancer care but also positive implications in longevity and rejuvenation research. Starting this week, we are embarking on a new insider-led Series A-1 equity round with the goal of raising $6-8M. This past Thursday, we had our first call with current investors and received $2.5M in verbal commitments thus far. EFTA00450648 Attached is an updated deck and a term sheet for the upcoming Series A-1 round. Please do not hesitate to reach out to me. Best regards, Paul EFTA00450649